-
| Industry | Biotechnology |
|---|---|
| Sector | Healthcare |
| ISIN | None |
| CurrencyCode | USD |
| Exchange | NASDAQ |
| Dividend Yield | 0.0% |
|---|---|
| Target Price | None |
| PE Ratio | None |
| Market Cap | None |
| Beta | nan |
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CINGW using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024